Genmab Revenue Jumps 25% on Strong Royalty Growth and FDA Approval
Event summary
- Genmab's Q1 2026 revenue increased 25% year-over-year to $896 million, driven by higher royalties from DARZALEX and Kesimpta.
- FDA approved a supplemental biologics license application (sBLA) to remove the recommendation for 24-hour hospitalization for patients with third-line relapsed/refractory DLBCL.
- Royalty revenue rose 26% to $742 million, primarily from increased net sales of DARZALEX and Kesimpta.
- Operating expenses increased 25% to $606 million, reflecting investments in late-stage portfolio and global commercialization capabilities.
- Acquisition and integration-related charges totaled $45 million, primarily due to the Merus acquisition.
The big picture
Genmab's strong Q1 2026 performance highlights its strategic focus on leveraging royalty streams from key partnerships with Johnson & Johnson and Novartis. The FDA approval for EPKINLY underscores the company's ability to navigate regulatory hurdles, positioning it for potential launches of Rina-S and petosemtamab. The integration of Merus and continued investment in its late-stage portfolio reflect a broader industry trend of consolidation and innovation in biotechnology.
What we're watching
- Regulatory Dynamics
- The FDA approval for EPKINLY could accelerate its market adoption and impact patient treatment protocols.
- Execution Risk
- The pace at which Genmab can integrate Merus and advance its late-stage portfolio will determine its long-term growth trajectory.
- Market Positioning
- How Genmab sustains its royalty revenue growth from DARZALEX and Kesimpta amid competitive pressures in the biotech sector.
Related topics